Product Description
Versavo 100 mg/4 mL Solution for Infusion contains Bevacizumab 100 mg, a recombinant humanized monoclonal antibody and anti-cancer biologic manufactured by Dr. Reddys Laboratories Ltd. It is supplied as a 4 mL vial (25 mg/mL) and is administered by intravenous infusion under medical supervision.
Bevacizumab works by inhibiting VEGF-A (vascular endothelial growth factor), thereby reducing the formation of new blood vessels that tumors need for growth and progression.
Versavo is indicated, depending on the approved regimen and cancer type, for conditions including metastatic colorectal cancer, advanced non-squamous NSCLC, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, ovarian/fallopian tube/primary peritoneal cancers, and metastatic breast cancer.
Key Product Details
| Particular |
Details |
| Brand |
VERSAVO 100 MG |
| Active Ingredient |
Bevacizumab |
| Strength |
100 mg/4 mL |
| Dosage Form |
Concentrate/Solution for IV infusion |
| Manufacturer |
Dr. Reddys Laboratories Ltd. |
| Pack |
1 vial 4 mL |
| Storage |
Refrigerate at 28C; do not freeze |
| Prescription |
Prescription medicine |
Frequently Asked Questions (FAQ)
1. What is Versavo 100 mg used for?
Versavo contains bevacizumab and is used with appropriate cancer treatment regimens for several advanced or metastatic cancers, including colorectal, lung, kidney, ovarian, cervical and certain brain cancers.
2. What is the composition of Versavo 100 mg?
Each 4 mL vial contains Bevacizumab 100 mg (25 mg/mL).
3. How is Versavo 100 mg administered?
It is administered as a slow intravenous infusion by a qualified healthcare professional. It should not be self-administered.
4. How does Versavo work?
It blocks VEGF-A, a protein involved in the formation of new blood vessels. This can reduce the blood supply supporting tumor growth.
5. Does Versavo require refrigeration?
Yes. It should generally be stored at 28C and should not be frozen.
6. What are common side effects?
Possible adverse effects include high blood pressure, protein in urine, fatigue, headache, nosebleeds and gastrointestinal symptoms.
7. Are there serious risks associated with bevacizumab?
Important risks can include serious bleeding, blood clots, gastrointestinal perforation, hypertension, kidney-related problems and impaired wound healing. Patients require appropriate medical monitoring.
8. Can Versavo be given before surgery?
Bevacizumab can affect wound healing, so its use around the time of surgery requires careful planning by the treating oncology team.
9. Is Versavo a prescription medicine?
Yes. It should be used only under the supervision and prescription of an appropriately qualified healthcare professional.
10. Is Versavo available in other strengths?
Yes. Versavo is available in 100 mg/4 mL and 400 mg/16 mL single-use vial presentations.
Targeted Anti-Angiogenic Therapy for CancerVERSAVO 100 harnesses the power of bevacizumab to inhibit angiogenesis, a critical factor in tumor growth. By preventing the formation of new blood vessels that supply nutrients to tumors, this medication supports the management of certain cancers. Its efficacy and safety are established when administered under close supervision by healthcare professionals.
Guidelines for Secure AdministrationThis product is intended for single use and should always be administered via IV infusion after proper dilution in accordance with medical advice. Precise dosage and infusion rate are determined by a physician, customized to the patient's cancer type and condition. Adhering to prescribed protocols ensures both effectiveness and patient safety.
Optimal Storage and Handling PracticesVERSAVO 100 must be kept refrigerated between 2C and 8C, and it should never be frozen. The single-use vial eliminates contamination risks. Before infusion, verify the expiry date and ensure the concentrate is visually inspected for any particulates or discoloration. Proper storage and handling maintain the product's integrity and therapeutic value.
FAQ's of BEVACIZUMAB INJ(VERSAVO):
Q: How is VERSAVO 100 (Bevacizumab) administered to patients?
A: VERSAVO 100 is administered intravenously following dilution, typically in a healthcare setting. The infusion process and dosage are managed by a medical professional as per the prescribed protocol for the patient's specific cancer.
Q: What is the primary function of VERSAVO 100 in cancer treatment?
A: The main function of VERSAVO 100 is to inhibit angiogenesis, which is the formation of new blood vessels that support tumor growth. This action helps limit the tumor's nutrient supply, slowing its progression.
Q: When should VERSAVO 100 be used during cancer therapy?
A: Usage timing is determined by the treating physician based on the patient's medical condition, type of cancer, and overall treatment plan. It is not self-administered and is only given under direct medical supervision.
Q: Where should VERSAVO 100 be stored and for how long?
A: VERSAVO 100 should be stored in a refrigerator at 2C to 8C and never frozen. Always check the packaging for the specific expiry date before administration.
Q: What steps are followed to prepare VERSAVO 100 for infusion?
A: The vial's contents must be diluted with an appropriate infusion solution before administration. Preparation and infusion are done in a clinical environment by qualified professionals to ensure accuracy and sterility.
Q: Who should use VERSAVO 100 and under what circumstances?
A: VERSAVO 100 is intended for adult cancer patients requiring anti-angiogenic therapy, as determined by a physician. Dosage and duration are strictly based on the prescription and patient-specific factors.
Q: What are the benefits of using VERSAVO 100 as part of cancer therapy?
A: VERSAVO 100 has demonstrated benefits in controlling tumor growth by inhibiting blood vessel formation, which may improve treatment outcomes in certain cancers when combined with other therapies, as advised by a specialist.